

Ref. No: FOI1757  
Date: 16/05/2025  
Subject: Giant cell arteritis (GCA)

## REQUEST & RESPONSE

**Q1. Does your trust or health board treat giant cell arteritis (GCA)? If not, please provide the name of the hospital or trust that you refer GCA patients to.**

YES

**Q2. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were:**

- **Admitted as an inpatient**

Month	Inpatient admissions
January	<5
February	<5
March	7
Total	12

- **Treated in A&E**

Month	A&E Attendances
January	<5
February	<5
March	<5
Total	8

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.

#### REMAINING QUESTIONS FOR PHARMACY

**Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:**

- **Tocilizumab – for any disease - 21**
- **Tocilizumab for rheumatoid arthritis (RA) only - 15**
- **Tocilizumab for giant cell arteritis (GCA) only - 0**

**Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? - 0**

**Q5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab? - 0**